Wednesday, July 8, 2026

pharma · Non-small Cell Lung Cancer · Epilepsy

Eisai

Eisai clinical programs — 22 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Tokyo, Japan, JP HQ
41 Employees
NMPA registrant Type
Company details
Intelligence · Clinical Programs

Eisai projects

22 ClinicalTrials.gov programs sponsored by Eisai.

Eisai has 22 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. E0302 (mecobalamin)

    Eisai Co.,

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 small molecule completed

    1 trial
  2. LECANEMAB

    Eisai Co.,

    Early Preclinical Alzheimer’s Disease and Intermediate Amyloid, Preclinical Alzheimer’s Disease and Elevated Amyloid

    phase 3 small molecule active

    1 trial
  3. Lecanemab

    Eisai Co.,

    Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.

    phase 3 small molecule active

    1 trial
  4. Pembrolizumab

    Eisai Co.,

    Endometrial Neoplasms

    phase 3 small molecule completed

    1 trial
  5. Zonisamide

    Eisai Co.,

    Epilepsy

    phase 3 small molecule completed

    1 trial
  6. bexarotene

    Eisai Co.,

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial
  7. perampanel

    Eisai Co.,

    Epilepsy

    phase 3 small molecule completed

    2 trials
  8. BB-1701-G000-205

    Eisai Co.,

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial
  9. E2007-G000-236

    Eisai Co.,

    Childhood Epilepsy

    phase 2 small molecule active

    1 trial
  10. E7080

    Eisai Co.,

    Solid Tumors

    phase 2 small molecule completed

    1 trial
  11. E7090

    Eisai Co.,

    Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial
  12. E7386-G000-201

    Eisai Co.,

    colorectal cancer, melanoma, hepatocellular carcinoma

    phase 2 small molecule active

    1 trial
  13. E7386-J081-102

    Eisai Co.,

    Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor

    phase 2 small molecule active

    1 trial
  14. FOLFIRI

    Eisai Co.,

    Colon Cancer

    phase 2 small molecule terminated

    1 trial
  15. Lenvatinib

    Eisai Co.,

    Osteosarcoma

    phase 2 small molecule completed

    1 trial
  16. MORAb-202-G000-201

    Eisai Co.,

    Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).

    phase 2 small molecule active

    1 trial
  17. Tazemetostat

    Eisai Co.,

    Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial
  18. eribulin mesylate + erlotinib

    Eisai Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial
  19. E0302 SR1

    Eisai Co.,

    Healthy Subjects

    phase 1 small molecule completed

    1 trial
  20. E6007

    Eisai Co.,

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  21. E7080

    Eisai Co.,

    Cancer: Solid Tumors

    phase 1 small molecule completed

    1 trial
  22. E7766

    Eisai Co.,

    Lymphoma

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Eisai have?

22 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.